Skip to main content
. Author manuscript; available in PMC: 2009 Jun 1.
Published in final edited form as: Biochim Biophys Acta. 2008 Feb 20;1783(6):1211–1219. doi: 10.1016/j.bbamcr.2008.01.032

Figure 2.

Figure 2

TGZ, sulindac sulfide, and indomethacin suppress EP4 expression dose-dependently in T98G cells. T98G cells were treated with Vehicle (0.1% Me2SO), 20 µM TGZ, 30 µM sulindac sulfide or 50 µM indomethacin for 48h. EP2 and EP4 expression were measured by Western blot analysis (A). For real-time RT-PCR analysis, T98G cells were treated with additional 4 PPARγligands (30 µM CGZ, 10 µM RGZ, 10 µM MCC, and 10 µM PGZ)(B). T98G cells were treated with these 3 drugs in different concentrations as indicated (C). The bar graphs represent mean ± S.D. of EP2 or EP4/Actin of three experiments, each done in duplicate. *P<0.01, significant compared with Vehicle. CGZ: Ciglitazone, RGZ: Rosiglitazone, MCC: MCC-555, PGZ: Pioglitazone.